Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2026)
Lyell Immunopharma (LYEL) reported Asset Utilization Ratio of 0.0 for Q1 2026, down 36.43% on a YoY basis from 0.0 in Q1 2025, and down 6.74% sequentially from 0.0 in Q4 2025.
Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 6 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Utilization Ratio fell 36.43% year-over-year to 0.0; the trailing twelve-month figure through Mar 2026 stood at 0.0 (down 36.43% YoY), and the FY2025 full-year result was 0.0, down 11.86% from the prior year.
- Asset Utilization Ratio eased to 0.0 in Q1 2026, from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.09 in Q1 2023 to a low of 0.0 in Q2 2024.
- A 5-year average of 0.02 and a median of 0.0 in 2025 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio soared 1063.08% in 2023 and plunged 99.9% in 2024, its largest moves.
- Tracing LYEL's Asset Utilization Ratio over 5 years: stood at 0.09 in 2022, then slumped by 99.81% to 0.0 in 2023, then slumped by 34.69% to 0.0 in 2024, then decreased by 12.42% to 0.0 in 2025, then fell by 6.74% to 0.0 in 2026.
- Business Quant data shows LYEL's Asset Utilization Ratio at 0.0 in Q1 2026, 0.0 in Q4 2025, and 0.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.06 |
| Jun 30, 2023 | 0.06 |
| Mar 31, 2023 | 0.09 |
| Dec 31, 2022 | 0.09 |
| Sep 30, 2022 | 0.04 |
| Jun 30, 2022 | 0.04 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.01 |